Hepatic Cell News 3.01 January 18, 2019 | |
| |
TOP STORYDemethylation of CCAAT/enhancer-binding protein-beta enhancer reactivated a self-reinforcing enhancer-target loop via direct transcriptional up-regulation of enhancer RNA. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Mechanisms Involved in the Activation of C/EBPα by Small Activating RNA in Hepatocellular Carcinoma Scientists confirmed CCAAT enhancer-binding protein A (CEBPA)-saRNA decreased proliferation and migration in the differentiated lines. The undifferentiated line showed saRNA-induced increase in CEBPA but with no loss in proliferation. [Oncogene] Abstract Both in vitro and in vivo experiments results confirmed that overexpression of Ptn-dt significantly promoted the proliferation of mouse hepatocellular carcinoma cells. RNA pulldown assay showed that Ptn-dt could interact with the HuR protein. [Oncogene] Abstract miR-192 was secreted and transmitted through exosomes from hepatitis C virus (HCV) replicating hepatocytes into hepatic stellate cells (HSCs). Exosomal transferred miR-192 upregulated fibrogenic markers in HSCs through transforming growth factor β1 upregulation, resulting in the activation and transdifferentiation of HSCs into myofibroblasts. [Mol Ther Nucleic Acids] Full Article | Graphical Abstract Researchers showed that bazedoxifene acetate (BAZ) inhibited STAT3 phosphorylation (P-STAT3) and expression of STAT3 downstream genes, inducing apoptosis in liver cancer cells. BAZ inhibited P-STAT3 induced by IL-6, but not by leukemia inhibitory factor. [Cancer Sci] Abstract NOD1 Activates Autophagy to Aggravate Hepatic Ischemia-Reperfusion Injury in Mice Scientists found that NOD1 was upregulated during hepatic ischemia/reperfusion injury and was associated with an activation of the autophagic signaling pathway. Moreover, levels of Atg5, a critical protein associated with autophagy, were decreased when NOD1 was inhibited by NOD1 small interfering RNA. [J Cell Biochem] Abstract The authors found that the high level expression of cyclin B1 (CCNB1) was closely associated with poor prognosis in hepatocellular carcinoma (HCC) patients. Knockdown of CCNB1 by RNA interference significantly inhibited cell proliferation, migration and invasion in HCC. [Cancer Cell Int] Full Article Investigators demonstrated that propyl gallate (PG) inhibited hepatocellular carcinoma cell proliferation in vitro and in zebrafish models in vivo in a dose- and time-dependent manner. PG also induced cell apoptosis and increased the number of necrotic cells in a time- and dose-dependent manner as determined using a high-content analysis system. [PLoS One] Full Article miR-134 inhibited hepatic stellate cell (HSC) proliferation, and decreased the expression of smooth muscle actin and collagen I in HSCs, whereas the miR-134 inhibitor increased HSC activation. [Biochem Cell Biol] Abstract Subscribe to one of our other 19 science newsletters such as Intestinal Cell News & Pancreatic Cell News. | |
| |
REVIEWSTherapeutic Advances for Patients with Intermediate Hepatocellular Carcinoma In this review, the authors introduce current treatment strategies for intermediate hepatocellular carcinoma , discuss their advantages and disadvantages, and propose future directions. [J Cell Physiol] Abstract Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
INDUSTRY NEWSExelixis, Inc. announced that the U.S. FDA approved CABOMETYX® tablets for patients with hepatocellular carcinoma who have been previously treated with sorafenib. [Exelixis, Inc] Press Release Acquist Announces Issuance of Two U.S. Patents Covering Its Drug Library of Novel Small Molecules Acquist Therapeutics, Inc. announced that the U.S. Patent Office has issued two new patents covering the Acquist investigational drug library. These patents cover compounds intended for treatment of patients with NASH, gout, and other illnesses. [Acquist Therapeutics, Inc.] Press Release Ascletis Pharma Inc. and Suzhou Alphamab Co., Ltd. jointly announced that Ascletis’ subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for anti-PD-L1 KN035 to treat hepatitis B and other viral diseases in Greater China. [Suzhou Alphamab Co. Ltd (PR Newswire Association LLC)] Press Release | |
| |
EVENTSNEW Cell Symposia: Hallmarks of Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Senior Scientific Officer – Cancer Biology (Cancer Research UK Beatson Institute) Postdoctoral Researcher – Cancer Biology (University of Pennsylvania – Perelman School of Medicine) Postdoctoral Position – Nonalcoholic Steatohepatitis (University of Southern Denmark) PhD Position – Cancer Biology (German Cancer Research Center) Postdoctoral Researcher – Hepatic Research (Karolinska Institutet) Postdoctoral Scholar – Liver Disease (Pennsylvania State University) Postdoctoral Position – Liver Disease (University of Illinois) Research Associate – Cancer Structural Biology (University of British Columbia) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|